Who are thrombolysis therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intravenous thrombolysis agents, Intravenous rhTNK-tPA, Low-dose rtPA, Intravenous rhPro-UK, Intra-Arterial TNK and Albumin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/thrombolysis-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

thrombolysis therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

thrombolysis therapy (thrombolysis therapy) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombolytic agent. Area: Cardiovascular.

phase 3 Thrombolytic agent Fibrin; plasminogen/plasmin pathway Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

thrombolysis therapy (thrombolysis therapy) — Leiden University Medical Center. Thrombolysis therapy dissolves blood clots by activating fibrinolytic enzymes to break down fibrin and restore blood flow in occluded vessels.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
thrombolysis therapy TARGET	thrombolysis therapy	Leiden University Medical Center	phase 3	Thrombolytic agent	Fibrin; plasminogen/plasmin pathway
Intravenous thrombolysis agents	Intravenous thrombolysis agents	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Thrombolytic agent / Fibrinolytic agent	Plasminogen / Fibrin
Intravenous rhTNK-tPA	Intravenous rhTNK-tPA	Xinqiao Hospital of Chongqing	phase 3	Thrombolytic agent / Fibrinolytic	Plasminogen / Fibrin
Low-dose rtPA	Low-dose rtPA	The George Institute	phase 3	Thrombolytic agent	Plasminogen
Intravenous rhPro-UK	Intravenous rhPro-UK	First Affiliated Hospital Xi'an Jiaotong University	phase 3	Thrombolytic agent	Plasminogen
Intra-Arterial TNK and Albumin	Intra-Arterial TNK and Albumin	Tianjin Huanhu Hospital	phase 3	Thrombolytic agent with albumin carrier	Fibrin; plasminogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombolytic agent class)

First Affiliated Hospital Xi'an Jiaotong University · 1 drug in this class
Leiden University Medical Center · 1 drug in this class
The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). thrombolysis therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/thrombolysis-therapy. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing